

## CONTENTS

NOTE TO THE READER .....	9
LIST OF PARTICIPANTS .....	11
PREAMBLE .....	17
Background .....	17
Objective and Scope .....	17
Selection of Topics for Monographs .....	18
Data for Monographs .....	19
The Working Group .....	19
Working Procedures .....	19
Exposure Data .....	20
Studies of Cancer in Humans .....	21
Studies of Cancer in Experimental Animals .....	25
Other Relevant Data .....	27
Summary of Data Reported .....	28
Evaluation .....	30
References .....	34
GENERAL REMARKS .....	39
THE MONOGRAPHS	
<b>Hepatitis B virus</b> .....	45
1. Exposure data .....	45
1.1 Structure and biology of hepatitis B virus (HBV) .....	45
1.1.1 Structure of the virus .....	45
1.1.2 Structure of HBV genome and gene products .....	45
1.1.3 Replication of HBV .....	47
1.1.4 HBV and related animal viruses .....	48
1.1.5 HBV mutants .....	48
1.1.6 Host range and target cells of HBV infection .....	50
1.2 Methods of detection .....	50
1.2.1 In serum and plasma .....	50
1.2.2 In liver tissues .....	52

## CONTENTS

1.2.3	Interpretation of serological markers of HBV infection	53
1.3	Epidemiology of infection	54
1.3.1	Transmission	54
1.3.2	Determinants of chronic infection	55
1.3.3	Global patterns of chronic infection	55
1.4	Clinical diseases (other than cancer)	57
1.4.1	Acute infection	59
1.4.2	Chronic infection	59
1.4.3	Extrahepatic manifestations	61
1.5	Therapy and immunoprophylaxis	62
1.5.1	Therapy	62
1.5.2	Immunoprophylaxis	63
2.	Studies of cancer in humans	66
2.1	Case series and case reports	66
2.1.1	Hepatocellular carcinoma	66
2.1.2	Other cancers	67
2.2	Descriptive studies	67
2.3	Cohort studies	67
2.3.1	Prospective studies of general population groups	67
2.3.2	Prospective studies of blood donors	70
2.3.3	Prospective studies of populations with pre-existing disease	71
2.4	Case-control studies	72
2.4.1	Hepatocellular carcinoma	72
2.4.2	Cholangiocarcinoma	97
2.4.3	Other cancers	97
3.	Studies of cancer in experimental animals	97
3.1	Primates	97
3.1.1	Infection with HBV	97
3.1.2	Infection with HBV with concomitant administration of chemical carcinogens	99
3.2	Transgenic mice	100
3.2.1	With no concomitant administration of chemical carcinogens	100
3.2.2	With concomitant administration of known chemical carcinogens	100
3.3	Woodchucks ( <i>Marmota monax</i> )	103
3.3.1	Hepatocellular carcinoma in woodchucks naturally infected with woodchuck hepatitis virus	103
3.3.2	Hepatocellular carcinoma in woodchucks experimentally infected with woodchuck hepatitis virus	105
3.3.3	Hepatocellular carcinoma in woodchucks experimentally infected with ground squirrel hepatitis virus	106

## CONTENTS

3.4	Ground squirrels, ducks and other species	106
3.4.1	Beechey ground squirrels	106
3.4.2	Richardson ground squirrels	108
3.4.3	Ducks	109
3.4.4	Other species	113
4.	Other relevant data	113
4.1	Pathology	113
4.1.1	Acute hepatitis	113
4.1.2	Chronic hepatitis	114
4.1.3	Cirrhosis	114
4.1.4	Evolution of hepatocellular carcinoma from cirrhosis	115
4.1.5	Hepatocellular carcinoma	116
4.2	Molecular biology	116
4.2.1	Integration of HBV DNA	117
4.2.2	Expression and potential oncogenic properties of HBV gene products	120
4.2.3	Genetic alterations in hepatocellular carcinoma	123
4.3	Other observations relevant to possible mechanisms of action of HBV in carcinogenesis	125
4.3.1	Cell division and tissue regeneration in response to HBV infection	125
4.3.2	Immune response	125
4.3.3	Hepatocellular carcinoma-associated tumour markers	126
4.3.4	Role of aflatoxins and possible modification of the effect of HBV	126
5.	Summary of data reported and evaluation	126
5.1	Exposure data	126
5.2	Human carcinogenicity data	127
5.3	Animal carcinogenicity data	128
5.4	Other relevant data	128
5.5	Evaluation	129
6.	References	129
	<b>Hepatitis C virus</b>	<b>165</b>
1.	Exposure data	165
1.1	Structure and biology of hepatitis C virus (HCV)	165
1.1.1	Structure of the virus	165
1.1.2	Structure of HCV genome and gene products	165
1.1.3	Replication and gene expression of HCV	165
1.1.4	HCV animal models	167
1.1.5	Genotypes of HCV	167

## CONTENTS

1.1.6	Host range and target cells of HCV infection	167
1.2	Methods of detection	168
1.2.1	In serum and plasma	168
1.2.2	In liver tissues	170
1.2.3	Interpretation of serological markers of HCV infection	170
1.3	Epidemiology of infection	171
1.3.1	Parenteral exposure	173
1.3.2	Non-parenteral exposure	175
1.4	Clinical diseases (other than cancer)	179
1.4.1	Acute infection	179
1.4.2	Chronic infection	179
1.4.3	Extrahepatic manifestations	180
1.5	Therapy	181
1.5.1	Acute and fulminant HCV infection	181
1.5.2	Chronic HCV infection	181
2.	Studies of cancer in humans	182
2.1	Case series	182
2.2	Cohort studies	182
2.3	Case-control studies	186
2.3.1	First-generation assays	186
2.3.2	Second-generation assays	190
2.4	Modifying effects of seropositivity for hepatitis B surface antigen	195
3.	Studies of cancer in experimental animals	195
4.	Other relevant data	198
4.1	Pathology	198
4.1.1	Acute infection	198
4.1.2	Chronic infection	199
4.1.3	Cirrhosis and hepatocellular carcinoma	199
4.2	Molecular biology	199
4.3	Other observations relevant to possible mechanisms of action of HCV in carcinogenesis	200
5.	Summary of data reported and evaluation	200
5.1	Exposure data	200
5.2	Human carcinogenicity data	201
5.3	Animal carcinogenicity data	202
5.4	Other relevant data	202
5.5	Evaluation	202
6.	References	202

## CONTENTS

<b>Hepatitis D virus</b> .....	223
1. Exposure data .....	223
1.1 Structure and biology of hepatitis D virus (HDV) .....	223
1.1.1 Structure of the virus .....	223
1.1.2 Structure of HDV genome and gene products .....	223
1.1.3 Replication of HDV .....	225
1.1.4 HDV-related animal models .....	225
1.1.5 HDV mutants .....	225
1.1.6 HDV-HBV interaction .....	226
1.1.7 Host range and target cells of HDV infection .....	226
1.2 Methods of detection .....	227
1.2.1 In serum and plasma .....	227
1.2.2 In liver tissues .....	227
1.2.3 Serological markers of HDV infection .....	228
1.3 Epidemiology of infection .....	229
1.3.1 Prevalence .....	229
1.3.2 Transmission .....	232
1.4 Clinical diseases (other than cancer) .....	233
1.4.1 Acute infection .....	233
1.4.2 Chronic infection .....	234
1.5 Therapy and immunoprophylaxis .....	235
1.5.1 Therapy .....	235
1.5.2 Immunoprophylaxis .....	235
2. Studies of cancer in humans .....	236
2.1 Case series .....	236
2.2 Case-control studies .....	236
3. Studies of cancer in experimental animals .....	239
4. Other relevant data .....	239
4.1 Pathology .....	239
4.1.1 Acute infection .....	239
4.1.2 Chronic infection .....	240
4.1.3 Cirrhosis .....	240
4.2 Other observations relevant to possible mechanisms of action of HDV in carcinogenesis .....	240
5. Summary of data reported and evaluation .....	241
5.1 Exposure data .....	241
5.2 Human carcinogenicity data .....	242
5.3 Animal carcinogenicity data .....	242
5.4 Other relevant data .....	242
5.5 Evaluation .....	242

## CONTENTS

6. References .....	242
SUMMARY OF FINAL EVALUATIONS .....	255
SUPPLEMENTARY CORRIGENDA TO VOLUMES 1-58 .....	257
CUMULATIVE INDEX TO THE <i>MONOGRAPHS</i> SERIES .....	259

## NOTE TO THE READER

The term 'carcinogenic risk' in the *IARC Monographs* series is taken to mean the probability that exposure to an agent will lead to cancer in humans.

Inclusion of an agent in the *Monographs* does not imply that it is a carcinogen, only that the published data have been examined. Equally, the fact that an agent has not yet been evaluated in a monograph does not mean that it is not carcinogenic.

The evaluations of carcinogenic risk are made by international working groups of independent scientists and are qualitative in nature. No recommendation is given for regulation or legislation.

Anyone who is aware of published data that may alter the evaluation of the carcinogenic risk of an agent to humans is encouraged to make this information available to the Unit of Carcinogen Identification and Evaluation, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 08, France, in order that the agent may be considered for re-evaluation by a future Working Group.

Although every effort is made to prepare the monographs as accurately as possible, mistakes may occur. Readers are requested to communicate any errors to the Unit of Carcinogen Identification and Evaluation, so that corrections can be reported in future volumes.

This volume is dedicated to Dr Lorenzo Tomatis, who initiated the *IARC Monographs* series in 1971 and retired in December 1993 after 12 years as Director of the Agency. The unflagging integrity and wisdom of Lorenzo Tomatis are the foundations for the respect that the *Monographs* command internationally.